the invention concerns the use of compound of formula 1 for imaging vessel , heart , and kidney diseases for which inflammation and / or mitochondrial dysfunction are major contributing factor . wherein x1 and x2 are independently from each other a hydrogen atom or a halogen atom , r1 and r2 are independently from each other a hydrogen atom , alkyl group having 1 to 10 carbon ( s ), a halogen - substituted alkyl group having 1 to 10 carbon ( s ) or radioisotope , and r3 is a halogen substituted alkyl group having 1 to 5 carbon ( s ) or a radioisotope thereof . in a preferred embodiment of the compound of formula 1 , the halogen atom in r3 is a fluorine atom , an iodine atom or a bromine atom and , more preferably , a fluorine atom or an iodine atom . in a preferred embodiment of the compound of formula 1 , the radioisotope in the present invention is 11 c , 18 f , 123 i and more preferably 18 f . in a preferred embodiment of the use the diseases are selected from aneurysms , athersclerosis , cardiomyopathy and some other heart diseases , heart failure , inflammatory valvular disease , coronary artery disease , endocarditis , atheroma , arteriosclerosis , inflammatory diseases of the heart , such as myocarditis , inflammatory cardiomyopathy , renal diseases , autoimmune diseases and nephrosclerosis . in a preferred embodiment of the use the kidney diseases are selected from ischemia — reperfusion injury , acute and / or chronic renal failure , nephrosclerosis , autoimmune diseases affecting the kidneys . in a more preferred embodiment the diseases are selected from myocarditis , atheroma , arteriosclerosis . the alkyl group having 1 to 10 carbon ( s ) means a linear or branched alkyl group and its examples are a methyl group , an ethyl group , an n - propyl group , an isopropyl group , an n - butyl group and an n - heptyl group . the halogen - substituted alkyl group having 1 to 10 carbon ( s ) means a linear or branched alkyl group where 1 to 3 halogen atom ( s ) is / are substituted for a hydrogen atom ( s ) and , preferably , it is an alkyl group substituted with fluorine or iodine atom ( s ). examples thereof are a fluoromethyl group , a 2 - fluoroethyl group , an 2 - iodoethyl group , a 5 - fluoroheptyl group and a 6 - bromohexyl group . the halogen - substituted alkyl group having 1 to 5 carbon ( s ) means a linear or branched alkyl group where 1 to 3 halogen atom ( s ) is / are substituted for a hydrogen atom ( s ) and , preferably , it is an alkyl group substituted with fluorine or iodine atom ( s ). examples thereof area fluoromethyl group , a 2 - fluoroethyl group , an 2 - iodoethyl group and a 5 - fluoroheptyl group . in a second aspect of the invention , the invention relates to the use of compound of formula 1 for imaging peripheral inflammatory disease , characterized by infiltration of white blood cells , e . g . osteomyelitis or rheumatoid arthritis for which inflammation and / or mitochondrial dysfunction are / is a major factor of incidence . in a third aspect of the invention , the invention relates to the use of compound of formula 1 for imaging autoimmune diseases . in a more preferred embodiment the autoimmune disease is selected from multiple sclerosis , rheumatoid arthritis , amyotrophic lateral sclerosis ( als ), and others the present invention will now be illustrated in more detail by way of the following examples . an oily sodium hydride ( 60 %) ( 5 . 1 mg ) was added to a solution of n -( 2 - hydroxy - 5 - methoxybenzyl )- n -( 5 - fluoro - 2 - phenoxyphenyl ) acetamide ( hereinafter , referred to as daa1123 ) ( 18 mg ) in n , n - dimethylformamide ( dmf ; 1 . 0 ml ) followed by stirring at 0 [ deg .] c ., 10 mg of fluoromethyl iodide ( fch2i ) were added thereto and the mixture was further stirred at 0 [ deg .] c . for 1 hour . water was added to the reaction solution , the mixture was extracted with ethyl acetate and the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate . the solvent was evaporated under reduced pressure and the resulting crude product was purified by a silica gel column chromatography ( chloroform : hexane : ethyl acetate = 1 : 3 : 1 ) to give 16 mg of the above - identified compound . production of n -( 2 -[ 18 f ] fluoromethyl - 5 - methoxybenzyl - n -( 5 - fluoro - 2 - phenoxyphenyl ) acetamide ( hereinafter , referred to as [ 18 f ] fmdaa1106 ) [ 18 f ] fluorine ([ 18 f ] f ) was produced by irradiation of 18 mev proton using 20 atom . % h218 o . after the irradiation , [ 18 f ] f was recovered from a target , separated from [ 18 o ] h2o by an anion - exchange resin dowex 1 - x8 , mixed with acetonitrile ( ch3cn , 1 . 5 ml ) containing kryptofix 2 . 2 . 2 . ( 25 mg ) and transferred from an irradiation chamber to a synthetic cell . after [ 18 f ] f was dried in a synthetic cell , diiodomethane ( ch2i2 ) was injected into a reactor at 130 [ deg .] c . together with the injection , [ 18 f ] f ch2i produced by helium gas was bubbled into a solution of 1 mg of daa1123 and sodium hydride ( 6 . 8 [ mu ] l , 0 . 5 g / 20 ml ) in dmf ( 300 ml ). after this process was maintained at room temperature for 10 minutes , the reaction mixture was injected into a reversed phase semi - separation hplc ( ymcj ′ sphere ods - h80 column ; 10 mm id * 250 mm ). a fraction of [ 18 f ] fmdaa1106 was collected where the mobile phase was ch3cn / h2o at the flow rate of 6 ml / minute . the solvent was evaporated under reduced pressure from this fraction and the residue was dissolved in saline ( 10 ml ) and passed through a 0 . 22 -[ mu ] m millipore filter to give [& lt ; 18 & gt ; f ] fmdaa1106 ( 110 mbq , n = 3 ) as the final preparation . ( condition for irradiation ; 15 minutes , 15 [ mu ] a ). incidentally , the synthetic time needed was about 45 minutes from the completion of the irradiation . the same operation as in example 1 was carried out where 1 - fluoro - 2 - tosyloxyethane ( fch2ch2ots ) was used instead of fluoromethyl iodide ( fch2i ) to give 20 mg of the above - identified compound . production of n -[ 2 -( 2 -[ 18 f ] fluoro ) ethyl - 5 - methoxybenzyl ]- n -( 5 - fluoro - 2 - phenoxyphenyl ) acetamide ( hereinafter , referred to as [ 18 f ] fedaa1106 ) the same operation as in example 2 was carried out where 2 - bromoethyl triflate ( brch2ch2otf ) was used instead of diiodomethane ( ch2i2 ) to give the above - identified compound . in accordance with the present invention , there is provided a compound which is useful as a ligand for pbr having a strong affinity and a high selectivity . in an external measurement of pbr where a sufficient signal has not been obtained until now , a ligand of pbr having a high affinity and a high selectivity is labeled with a positron nuclide whereby measurement of pbr in a living body is now possible . while the invention has been described in detail and with reference to specific examples thereof , it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof .